gefitinib has been researched along with exel-7647 in 4 studies
Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (exel-7647) | Trials (exel-7647) | Recent Studies (post-2010) (exel-7647) |
---|---|---|---|---|---|
5,231 | 566 | 2,919 | 13 | 3 | 12 |
Protein | Taxonomy | gefitinib (IC50) | exel-7647 (IC50) |
---|---|---|---|
Epidermal growth factor receptor | Homo sapiens (human) | 0.0252 | |
Receptor tyrosine-protein kinase erbB-2 | Homo sapiens (human) | 0.05 | |
Vascular endothelial growth factor receptor 1 | Homo sapiens (human) | 0.05 | |
Ephrin type-A receptor 2 | Homo sapiens (human) | 0.05 | |
Vascular endothelial growth factor receptor 2 | Homo sapiens (human) | 0.05 | |
Ephrin type-B receptor 4 | Homo sapiens (human) | 0.05 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (25.00) | 29.6817 |
2010's | 3 (75.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP | 1 |
Asquith, CRM; Drewry, DH; East, MP; Havener, TM; Johnson, GL; Laitinen, T; Morris, DC; Naegeli, KM; Wells, CI; Zuercher, WJ | 1 |
Aftab, DT; Bentzien, F; Cancilla, B; Chen, J; Chu, F; De Costa, A; Engell, K; Gendreau, SB; Jackman, L; Jaeger, CT; Joly, AH; Keast, P; Laird, AD; Lutman, J; Martini, JF; Meyer, SM; Shi, Y; Ventura, R; Wang, J; Yakes, FM; Yu, P; Zhang, W | 1 |
Cho, J; Chowhan, NM; Funke, R; Gadgeel, SM; Lara, PN; Lynch, TJ; Miller, VA; Mitchell, B; Pennell, NA; Pietanza, MC; Vrindavanam, N; Wakelee, HA; Yanagihara, RH | 1 |
1 trial(s) available for gefitinib and exel-7647
Article | Year |
---|---|
XL647--a multitargeted tyrosine kinase inhibitor: results of a phase II study in subjects with non-small cell lung cancer who have progressed after responding to treatment with either gefitinib or erlotinib.
Topics: Adult; Aged; Aged, 80 and over; Azabicyclo Compounds; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Treatment Outcome | 2012 |
3 other study(ies) available for gefitinib and exel-7647
Article | Year |
---|---|
The target landscape of clinical kinase drugs.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays | 2017 |
Design of a Cyclin G Associated Kinase (GAK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Set to Interrogate the Relationship of EGFR and GAK in Chordoma.
Topics: Aminoquinolines; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Chordoma; Drug Design; ErbB Receptors; HEK293 Cells; Humans; Intracellular Signaling Peptides and Proteins; Molecular Docking Simulation; Protein Binding; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Quinazolines | 2019 |
Inhibition of the T790M gatekeeper mutant of the epidermal growth factor receptor by EXEL-7647.
Topics: Animals; Antineoplastic Agents; Apoptosis; Azabicyclo Compounds; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Mice; Mice, Nude; Mice, SCID; Mutation; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Xenograft Model Antitumor Assays | 2007 |